Role of Imaging in Prostate Cancer

PET Clinics

Volumn 4, Issue 2, 2009, Pages 135-138

  Jadvar, Hossein ^a   Alavi, Abass ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone scan; Cancer; CT; Imaging; MRI; PET; Prostascint; Prostate; Ultrasound

Indexed keywords

ANDROGEN; CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; BONE METASTASIS; BONE SCINTISCANNING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE;

EID: 68849129330     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.05.003     Document Type: Review

References (52)

1. Benaron D.A. The future of cancer imaging. Cancer Metastasis Rev 21 (2002) 45-78
2. Seer. The Surveillance, Epidemiology, and End Results Program based within the Surveillance Research Program (SRP) at the National Cancer Institute (2008). Available at: http://seer.cancer.gov/statfacts/html/prost.html. Accessed: April 6, 2009.
3. Frank I.N., Graham Jr. S., and Nabors W.L. Urologic and male genital cancers. In: Holleb A.I., Fink D.J., and Murphy G.P. (Eds). Clinical oncology (1991), American Cancer Society, Atlanta (GA) 280-283
4. Kessler B., and Albertsen P. The natural history of prostate cancer. Urol Clin North Am 30 (2003) 219-226
5. Small E.J. Prostate cancer: incidence, management and outcomes. Drugs Aging 13 (1998) 71-81
6. Lin D.W., Noteboom J.L., Blumenstein B.A., et al. Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology 52 (1998) 366-371
7. Ploch N.R., and Brawer M.K. How to use prostate-specific antigen. Urology 43 2 Suppl (1994) 27-35
8. Lukes M., Urban M., Zalesky M., et al. Prostate-specific antigen: current status. Folia Biol (Praha) 47 (2001) 41-49
9. Boccon-Gibod L. [Prostate-specific antigen or PSA. Facts and probabilities]. Presse Med 24 (1995) 1471-1472 [in French]
10. Crawford E.D., DeAntoni E.P., and Ross C.A. The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl 25 (1996) 149-155
11. Safa A.A., Reese D.M., Carter D.M., et al. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature. Am J Clin Oncol 21 (1998) 323-326
12. Sella A., Konichezky M., Flex D., et al. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 38 (2000) 250-254
13. Beardo P., Fernandez P.L., Corral J.M., et al. Undetectable prostate specific antigen in disseminated prostate cancer. J Urol 166 3 (2001 Sep) 993
14. Dreicer R. Metastatic prostate cancer: assessment of response to systemic therapy. Semin Urol Oncol 15 (1997) 28-32
15. Bauer K.S., Figg W.D., Hamilton J.M., et al. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res 5 9 (1999) 2324-2329
16. Horti J., Dixon S.C., Logothetis C., et al. Increased transcriptional activity of PSA in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 79 (1999) 1588-1593
17. Lofters A., Juffs H.G., Pond G.R., et al. "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol 168 6 (2002) 2516-2520
18. Dong J.T., Rinker-Schaeffer C.W., Ichikawa T., et al. Prostate cancer: biology of metastasis and its clinical implications. World J Urol 14 (1996) 182-189
19. Yu K.K., and Hawkins R.A. The prostate: diagnostic evaluation of metastatic disease. Radiol Clin North Am 38 (2000) 139-157
20. Carroll P. Rising PSA after a radical treatment. Eur Urol 40 Suppl 2 (2001) 9-16
21. McMurtry C.T., and McMurtry J.M. Metastatic prostate cancer: complications and treatment. J Am Geriatr Soc 51 (2003) 1136-1142
22. Timme T.L., Satoh T., Tahir S.A., et al. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 4 3 (2003) 251-261
23. De la Taille A., Vancherot F., Salomon L., et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis 4 (2001) 204-212
24. Carlin B.I., and Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88 12 Suppl (2000) 2989-2994
25. Herold D.M., Hanlon A.L., Movsas B., et al. Age-related prostate cancer metastases. Urology 51 (1998) 985-990
26. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
27. Fossa S.D., Dearnaley D.P., Law M., et al. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 3 (1992) 331-335
28. Trapman J., and Brinkmann A.O. The androgen receptor in prostate cancer. Pathol Res Pract 192 (1996) 752-760
29. Culig Z., Hobisch A., Hittmair A., et al. Androgen receptor gene mutations in prostate cancer: implications for disease progression and therapy. Drugs Aging 10 (1997) 50-58
30. Culig Z., Klocker H., Bartsch G., et al. Androgen receptors in prostate cancer. Endocr Relat Cancer 9 (2002) 155-170
31. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26 (1999) 407-421
32. Yu K.K., and Hricak H. Imaging prostate cancer. Radiol Clin North Am 38 (2000) 59-85
33. Carey B.M. Imaging for prostate cancer. Clin Oncol (R Coll Radiol) 17 (2005) 553-559
34. Oehr P., and Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol 19 (2007) 259-264
35. Fuchsjager M., Shukla-Dave A., Akin O., et al. Prostate cancer imaging. Acta Radiol 49 (2008) 107-120
36. Hricak H., Schoder H., Pucar D., et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 30 (2003) 616-634
37. Fair W.R., Israeli R.S., and Heston W.D. Prostate-specific membrane antigen. Prostate 32 (1997) 140-148
38. Elgamal A.A., Holmes E.H., Su S.L., et al. Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 18 (2000) 10-16
39. Haseman M.K., Reed N.L., and Rosenthal S.A. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: positron emission tomography and biopsy correlation. Clin Nucl Med 21 9 (1996) 704-713
40. Haseman M.K., Rosenthal S.A., and Polascik T.J. Capromab pendetide imaging of prostate cancer. Cancer Biother Radiopharm 15 2 (2000) 131-140
41. Dotan Z.A. Bone imaging in prostate cancer. Nat Clin Pract Urol 5 (2008) 434-444
42. Modoni S., Calo E., Nardella G., et al. PSA and bone scintigraphy. Int J Biol Markers 12 (1997) 158-161
43. Lee C.T., and Oesterling J.E. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24 (1997) 389-394
44. Coleman R.E., Mashiter G., Whitaker K.B., et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 29 (1988) 1354-1359
45. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17 (1999) 3461-3467
46. DeLuca S.A., Castronovo F.P., and Rhea J.T. The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging. Clin Nucl Med 8 (1983) 11-13
47. Drelichman A., Decker D.A., Al-Sarraf M., et al. Computerized bone scan: a potentially useful technique to measure response in prostate carcinoma. Cancer 53 (1984) 1061-1065
48. Imbriaco M., Larson S.M., Yeung H.W., et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4 (1998) 1765-1772
49. Noguchi M., Kikuchi H., Ishibashi M., et al. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88 2 (2003) 195-201
50. Yahara J., Noghuchi M., and Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 92 (2003) 379-384
51. Rafii M., Firooznia H., Kramer E., et al. The role of computed tomography in evaluation of skeletal metastases. J Comput Tomogr 12 (1988) 19-24
52. Harisinghani M.G., Barentsz J.O., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 25 (2003) 2491-2499